ZA202105183B - Beta-lactam compounds or salts thereof for use in long-acting prevention or treatment of a glucose metabolism disorder - Google Patents
Beta-lactam compounds or salts thereof for use in long-acting prevention or treatment of a glucose metabolism disorderInfo
- Publication number
- ZA202105183B ZA202105183B ZA2021/05183A ZA202105183A ZA202105183B ZA 202105183 B ZA202105183 B ZA 202105183B ZA 2021/05183 A ZA2021/05183 A ZA 2021/05183A ZA 202105183 A ZA202105183 A ZA 202105183A ZA 202105183 B ZA202105183 B ZA 202105183B
- Authority
- ZA
- South Africa
- Prior art keywords
- beta
- salts
- treatment
- long
- glucose metabolism
- Prior art date
Links
- -1 Beta-lactam compounds Chemical class 0.000 title 1
- 208000018914 glucose metabolism disease Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962795917P | 2019-01-23 | 2019-01-23 | |
| PCT/CN2020/073283 WO2020151671A1 (en) | 2019-01-23 | 2020-01-20 | Beta-lactam compounds or salts thereof for use in long-acting prevention or treatment of a glucose metabolism disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202105183B true ZA202105183B (en) | 2023-01-25 |
Family
ID=71608720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2021/05183A ZA202105183B (en) | 2019-01-23 | 2021-07-22 | Beta-lactam compounds or salts thereof for use in long-acting prevention or treatment of a glucose metabolism disorder |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11419852B2 (en) |
| EP (1) | EP3914255A4 (en) |
| JP (1) | JP2022523303A (en) |
| KR (1) | KR20210117301A (en) |
| CN (2) | CN113423405A (en) |
| AU (2) | AU2020210983B2 (en) |
| BR (1) | BR112021014509A2 (en) |
| CA (1) | CA3126573A1 (en) |
| IL (1) | IL284950A (en) |
| MX (2) | MX2021008937A (en) |
| SG (2) | SG11202107678UA (en) |
| TW (2) | TWI807157B (en) |
| WO (2) | WO2020151671A1 (en) |
| ZA (1) | ZA202105183B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113679725A (en) * | 2020-11-30 | 2021-11-23 | 兰州大学 | Cephalosporin compound and application thereof in preparation of drugs for treating diabetes and complications |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9202298D0 (en) * | 1992-02-04 | 1992-03-18 | Ici Plc | Antibiotic compounds |
| BR0115852A (en) * | 2000-12-01 | 2003-12-23 | Ajinomoto Kk | Lactam compound or a pharmaceutically acceptable salt thereof, agent for enhancing sugar transportability, hypoglycemic agents and for preventing and / or treating diabetes, diabetic peripheral neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic macroangiopathy, impaired glucose tolerance or adipose. and pharmaceutical composition |
| WO2011047153A1 (en) * | 2009-10-15 | 2011-04-21 | President And Fellows Of Harvard College | Methods for modulating autoimmunity |
| US8951512B2 (en) * | 2010-05-04 | 2015-02-10 | New York University | Methods for treating bone disorders by characterizing and restoring mammalian bacterial microbiota |
| US9474744B2 (en) * | 2011-09-21 | 2016-10-25 | Stem Cell Medicine Ltd. | Beta-lactam compounds for treating diabetes |
| RU2017102997A (en) * | 2014-08-28 | 2018-09-28 | Академиш Медиш Центрум | COMPOUNDS AGAINST RALSTONIA PICKETTII FOR APPLICATION IN THE TREATMENT OF RESISTANCE TO INSULIN, AND ALSO THE METHOD FOR DIAGNOSTIC RESISTANCE TO INSULIN |
| CA2982943C (en) * | 2015-03-11 | 2019-07-23 | University Of Cincinnati | Compositions and methods for treating bacterial infection |
| US20190382826A1 (en) * | 2016-03-24 | 2019-12-19 | Quest Diagnostics Investments Llc | Methods for detecting bordetella |
| WO2018019031A1 (en) * | 2016-07-27 | 2018-02-01 | Institut Pasteur Of Shanghai, Chinese Academy Of Sciences | A pharmaceutical composition comprising an ionophore and a beta-lactam antibiotic and use thereof |
-
2020
- 2020-01-20 MX MX2021008937A patent/MX2021008937A/en unknown
- 2020-01-20 WO PCT/CN2020/073283 patent/WO2020151671A1/en active Application Filing
- 2020-01-20 BR BR112021014509-5A patent/BR112021014509A2/en unknown
- 2020-01-20 TW TW109101976A patent/TWI807157B/en active
- 2020-01-20 SG SG11202107678UA patent/SG11202107678UA/en unknown
- 2020-01-20 SG SG11202106694YA patent/SG11202106694YA/en unknown
- 2020-01-20 WO PCT/CN2020/073277 patent/WO2020151669A1/en active Application Filing
- 2020-01-20 TW TW109101975A patent/TWI820289B/en active
- 2020-01-20 AU AU2020210983A patent/AU2020210983B2/en active Active
- 2020-01-20 KR KR1020217025916A patent/KR20210117301A/en unknown
- 2020-01-20 CN CN202080007660.6A patent/CN113423405A/en active Pending
- 2020-01-20 CA CA3126573A patent/CA3126573A1/en active Pending
- 2020-01-20 JP JP2021543329A patent/JP2022523303A/en active Pending
- 2020-01-20 EP EP20744574.3A patent/EP3914255A4/en active Pending
- 2020-01-20 CN CN202311555678.1A patent/CN117338776A/en active Pending
- 2020-01-21 US US16/747,660 patent/US11419852B2/en active Active
- 2020-01-21 US US16/747,661 patent/US11564908B2/en active Active
-
2021
- 2021-07-19 IL IL284950A patent/IL284950A/en unknown
- 2021-07-22 ZA ZA2021/05183A patent/ZA202105183B/en unknown
- 2021-07-23 MX MX2024003112A patent/MX2024003112A/en unknown
-
2024
- 2024-07-31 AU AU2024205269A patent/AU2024205269A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020151669A1 (en) | 2020-07-30 |
| KR20210117301A (en) | 2021-09-28 |
| MX2021008937A (en) | 2021-11-12 |
| JP2022523303A (en) | 2022-04-22 |
| US11419852B2 (en) | 2022-08-23 |
| CN117338776A (en) | 2024-01-05 |
| CN113423405A (en) | 2021-09-21 |
| IL284950A (en) | 2021-09-30 |
| US20200230149A1 (en) | 2020-07-23 |
| EP3914255A4 (en) | 2022-10-05 |
| EP3914255A1 (en) | 2021-12-01 |
| TWI807157B (en) | 2023-07-01 |
| TW202042811A (en) | 2020-12-01 |
| US20200230105A1 (en) | 2020-07-23 |
| US11564908B2 (en) | 2023-01-31 |
| AU2020210983A1 (en) | 2021-08-12 |
| AU2020210983B2 (en) | 2024-05-16 |
| MX2024003112A (en) | 2024-04-05 |
| TWI820289B (en) | 2023-11-01 |
| SG11202106694YA (en) | 2021-07-29 |
| TW202042803A (en) | 2020-12-01 |
| WO2020151671A1 (en) | 2020-07-30 |
| SG11202107678UA (en) | 2021-08-30 |
| CA3126573A1 (en) | 2020-07-30 |
| BR112021014509A2 (en) | 2021-09-28 |
| AU2024205269A1 (en) | 2024-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL269354A (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
| IL260560B (en) | A sulfonyl-amino pyrimidinyl-amino benzamide compound for use as a medicament in a method for the treatment of cancer in a mammal | |
| MX2017004471A (en) | Triazolopyridine compounds and methods for the treatment of cystic fibrosis. | |
| MX2023008453A (en) | Methods of treating substance abuse. | |
| MX2009013625A (en) | Di(arylamino)aryl compound. | |
| SA515360469B1 (en) | Heterocyclic compounds for inhibiting glutaminase and their methods of use | |
| SG10201602326RA (en) | Combinations comprising brexpiprazole or a salt thereof and a second drug for use in the treatment of a cns disorder | |
| MX354509B (en) | Combinations of akt inhibitor compounds and vemurafenib, and methods of use. | |
| EP2190428A4 (en) | Heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | |
| IL212485A0 (en) | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | |
| MX2009004984A (en) | Methods for preserving renal function using xanthine oxidoreductase inhibitors. | |
| MX350745B (en) | Methods for treating fibromyalgia syndrome. | |
| WO2011055965A3 (en) | Methods for treating attention-deficit/hyperactivity disorder | |
| BR112014024693A2 (en) | a compound of formula / or a pharmaceutically acceptable salt or prodrug thereof; compound; pharmaceutical composition; method of treating a quinurenine 3-monooxygenase activity-mediated disorder or disorder in an individual in need of such treatment | |
| MX2018010878A (en) | Bicyclic aryl monobactam compounds and methods of use thereof for the treatment of bacterial infections. | |
| MX339829B (en) | Methods for stabilizing joint damage in subjects using xanthine oxidoreductase inhibitors. | |
| SG11201802010QA (en) | A group of compounds used for the treatment or prevention of hyperuricemia or gout | |
| ZA202105183B (en) | Beta-lactam compounds or salts thereof for use in long-acting prevention or treatment of a glucose metabolism disorder | |
| IL271212A (en) | Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor | |
| GB202103211D0 (en) | Pharmaceutical compounds for use in therapy | |
| EP4135671A4 (en) | Pirfenidone for coronavirus treatment | |
| NZ731591A (en) | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone | |
| EP2696873A4 (en) | Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria | |
| IL309002A (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
| EP2814485A4 (en) | Dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |